Vote Scores
Filings read through

Spyre Therapeutics, Inc.: how funds voted at the meeting of 27 May 2026

Ticker
SYRE
Meeting
Season
year to 30 June 2026
Filers reporting
325
Ballot items
5

325 filers on Form N-PX reported votes at the Spyre Therapeutics, Inc. meeting of 27 May 2026. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    3 nominees. 83.6% of the reported votes are for. 59 filers withheld from or voted against at least one nominee.

    708 vote records from 125 filers. 4 of the 124 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 37 fund families
    • For 35
    • Abstain or withhold 2
    • Against management 2
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    476 vote records from 324 filers. 71 of the 306 filers that marked the item voted against management. 18 filers gave no management mark.

    • Positions of 43 fund families
    • For 31
    • Against 12
    • Against management 12
  3. Item 3: Audit-related items (auditor ratification)

    236 vote records from 125 filers. 1 of the 124 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 37 fund families
    • For 37
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    22 vote records from 13 filers. 2 of the 13 filers that marked the item voted against management.

    • Positions of 3 fund families
    • For 2
    • Against 1
    • Against management 1
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    219 vote records from 117 filers. 2 of the 116 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 35 fund families
    • For 35

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Spyre Therapeutics, Inc., meeting of 27 May 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinForNo report
AllspringForFor
BlackRock and iSharesForFor
BNY MellonForNo report
Brighthouse FundsForFor
Capital Group and American FundsAgainst, against managementFor
Charles SchwabAgainst, against managementFor
Columbia ThreadneedleForFor
DimensionalAgainst, against managementFor
DWSForFor
EquitableForFor
FidelityForFor
First TrustForFor
Franklin TempletonForFor
Global XAgainst, against managementFor
Goldman SachsForFor
Guggenheim and RydexForFor
Hartford FundsForFor
InvescoAgainst, against managementFor
J.P. MorganForFor
Jackson National fundsForFor
Janus HendersonForNo report
John Hancock and ManulifeForFor
Lincoln FinancialForFor
MassMutualForFor
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementFor
NationwideForFor
Natixis and Loomis SaylesAgainst, against managementNo report
Neuberger BermanAgainst, against managementNo report
Northern Trust and FlexSharesAgainst, against managementFor
Nuveen and TIAAForFor
Pacific Life fundsForFor
PGIM and PrudentialAgainst, against managementFor
PrincipalForFor
ProShares and ProFundsForFor
Russell InvestmentsAgainst, against managementNo report
SEIAgainst, against managementFor
State Street and SPDRForFor
T. Rowe PriceForFor
TransamericaForFor
VanguardForFor
Victory CapitalForFor
VoyaForFor

Questions

How many filers reported votes at the Spyre Therapeutics, Inc. meeting?
325 Form N-PX filers reported votes at the meeting of 27 May 2026. On say-on-pay, 71 of 306 filers that marked the item voted against management (23.2%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Spyre Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Spyre Therapeutics, Inc. with a meeting date within three days of 27 May 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .